Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.
Fiche publication
Date publication
août 2019
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie
Tous les auteurs :
Zilli T, Franzese C, Bottero M, Giaj-Levra N, Förster R, Zwahlen D, Koutsouvelis N, Bertaut A, Blanc J, Roberto D'agostino G, Alongi F, Guckenberger M, Scorsetti M, Miralbell R
Lien Pubmed
Résumé
The ONE SHOT trial is the first phase I/II prospective, multicenter, single-arm study assessing the efficacy and safety of a single-dose SBRT for men with localized prostate cancer. Aim of this paper is to present the phase I results of a 19 Gy single fraction urethra-sparing SBRT with real-time electromagnetic tracking.
Mots clés
Monotherapy, Phase I/II trial, Prostate cancer, SBRT, Toxicity
Référence
Radiother Oncol. 2019 Aug 17;: